Payment overview · 2025
General Payments
$914.16
55 reported records · 10 companies
Healthcare provider profile · identity verified
Channing Janaci Hampton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TIFTON, GA · NPI 1164714416
Verified facts
What the public records show
CMS Open Payments records show Channing Janaci Hampton, M.D. received $914.16 in general payments during 2025 across 55 reported records.
Novo Nordisk Inc accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $300.86 | 32.9% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $202.50 | 22.1% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.47 | 15.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.26 | 8.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.33 | 6.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.47 | 4.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.77 | 4.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.56 | 2.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $18.38 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.56 | 1.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $914.16 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $202.50 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $188.72 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.68 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.69 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.33 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.04 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.04 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.30 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.51 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| NEXVIAZYME Normalized: nexviazyme |
Biological | GENZYME CORPORATION | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.56 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $4.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 205 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 319 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 319 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 105 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
205 | 58 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
319 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
319 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
105 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
208 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 168 |
| Montelukast Sodium | Montelukast Sodium | 694 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 691 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 578 | 109 |
| Gabapentin | Gabapentin | 536 | 129 |
| Losartan Potassium | Losartan Potassium | 445 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 416 | 96 |
| Tramadol Hcl | Tramadol Hcl | 386 | 76 |
| Lisinopril | Lisinopril | 355 | 79 |
| Omeprazole | Omeprazole | 346 | 86 |
| Metformin Hcl | Metformin Hcl | 319 | 80 |
| Mounjaro | Tirzepatide | 319 | 45 |
| Ozempic | Semaglutide | 319 | 53 |
| Potassium Chloride | Potassium Chloride | 307 | 76 |
| Pregabalin | Pregabalin | 273 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 241 | 87 |
| Furosemide | Furosemide | 241 | 61 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 227 | 60 |
| Trazodone Hcl | Trazodone Hcl | 220 | 57 |
| Famotidine | Famotidine | 219 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 214 | 50 |
| Dexlansoprazole Dr | Dexlansoprazole | 213 | 39 |
| Eliquis | Apixaban | 208 | 39 |
| Buspirone Hcl | Buspirone Hcl | 206 | 48 |
| Linzess | Linaclotide | 205 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 182 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 48 |
| Carvedilol | Carvedilol | 180 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 40 |
| Meloxicam | Meloxicam | 171 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 45 |
| Nifedipine Er | Nifedipine | 158 | 30 |
| Sertraline Hcl | Sertraline Hcl | 151 | 35 |
| Alprazolam | Alprazolam | 147 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 54 |
| Ezetimibe | Ezetimibe | 142 | 41 |
| Metformin Hcl Er | Metformin Hcl | 142 | 33 |
| Celecoxib | Celecoxib | 131 | 30 |
| Simvastatin | Simvastatin | 130 | 35 |
| Ipratropium Bromide | Ipratropium Bromide | 126 | 54 |
| Allopurinol | Allopurinol | 123 | 35 |
| Alendronate Sodium | Alendronate Sodium | 122 | 27 |
| Ondansetron Odt | Ondansetron | 117 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 36 |
| Fenofibrate | Fenofibrate | 113 | 27 |
| Clonidine Hcl | Clonidine Hcl | 112 | 31 |
| Glipizide | Glipizide | 111 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 20 |
| Rybelsus | Semaglutide | 105 | 31 |
| Fluconazole | Fluconazole | 103 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 23 |
| Spironolactone | Spironolactone | 93 | 22 |
| Lorazepam | Lorazepam | 92 | 22 |
| Baclofen | Baclofen | 90 | 19 |
| Temazepam | Temazepam | 88 | 12 |
| Donepezil Hcl | Donepezil Hcl | 87 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 87 | 19 |
| Azelastine Hcl | Azelastine Hcl | 83 | 29 |
| Ibuprofen | Ibuprofen | 77 | 11 |
| Nystatin | Nystatin | 77 | 32 |
| Farxiga | Dapagliflozin Propanediol | 75 | 17 |
| Bumetanide | Bumetanide | 73 | 17 |
| Sucralfate | Sucralfate | 73 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 17 |
| Prednisone | Prednisone | 69 | 37 |
| Jardiance | Empagliflozin | 66 | 16 |
| Movantik | Naloxegol Oxalate | 66 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 12 |
| Atenolol | Atenolol | 64 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 17 |
| Glimepiride | Glimepiride | 62 | 16 |
| Colchicine | Colchicine | 61 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 12 |
| Myrbetriq | Mirabegron | 60 | 14 |
| Bupropion Xl | Bupropion Hcl | 59 | 16 |
| Belsomra | Suvorexant | 57 | 12 |
| Vraylar | Cariprazine Hcl | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 53 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 14 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Finasteride | Finasteride | 49 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Meclizine Hcl | Meclizine Hcl | 47 | 12 |
| Novolog | Insulin Aspart | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 15 |
| Glipizide Er | Glipizide | 46 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 11 |
| Estradiol | Estradiol | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Levetiracetam | Levetiracetam | 45 | 14 |
| Primidone | Primidone | 45 | suppressed |
| Topiramate | Topiramate | 45 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 15 |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 29 |
| Clonidine | Clonidine | 40 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Lactulose | Lactulose | 39 | 15 |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Xifaxan | Rifaximin | 39 | suppressed |
| Mupirocin | Mupirocin | 38 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 11 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 11 |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 12 |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 11 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 33 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Metolazone | Metolazone | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 25 |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Roflumilast | Roflumilast | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Cefdinir | Cefdinir | 19 | 17 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Relistor | Methylnaltrexone Bromide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Corlanor | Ivabradine Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $914.16 · 55 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, EVENITY, FABRAZYME, LINZESS, MOUNJARO, NEXVIAZYME, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, TREMFYA, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error